Korro Bio (NASDAQ:KRRO) Major Shareholder Forest Baskett Purchases 207,100 Shares of Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Forest Baskett bought 207,100 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were acquired at an average price of $11.11 per share, with a total value of $2,300,881.00. Following the purchase, the insider owned 1,297,893 shares in the company, valued at $14,419,591.23. This trade represents a 18.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Korro Bio Stock Up 12.6%

NASDAQ KRRO traded up $1.45 during midday trading on Friday, hitting $12.95. The company had a trading volume of 552,892 shares, compared to its average volume of 237,193. Korro Bio, Inc. has a fifty-two week low of $5.20 and a fifty-two week high of $55.89. The stock has a market cap of $121.97 million, a price-to-earnings ratio of -1.38 and a beta of 2.98. The firm has a fifty day simple moving average of $10.90 and a two-hundred day simple moving average of $20.23.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($5.32) EPS for the quarter, missing the consensus estimate of ($1.93) by ($3.39). The firm had revenue of $1.29 million during the quarter, compared to analyst estimates of $0.43 million. Korro Bio had a negative net margin of 1,199.53% and a negative return on equity of 68.87%. As a group, equities analysts predict that Korro Bio, Inc. will post -9.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on KRRO shares. Cantor Fitzgerald boosted their target price on shares of Korro Bio from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Friday. Chardan Capital upgraded Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Thursday, January 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a research report on Friday, January 9th. Royal Bank Of Canada downgraded shares of Korro Bio from an “outperform” rating to a “sector perform” rating in a research report on Thursday, November 13th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Korro Bio in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $44.50.

Hedge Funds Weigh In On Korro Bio

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. bought a new position in shares of Korro Bio in the 3rd quarter valued at about $39,000. Wells Fargo & Company MN grew its position in shares of Korro Bio by 45.5% in the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after purchasing an additional 2,352 shares during the last quarter. Guggenheim Capital LLC bought a new position in Korro Bio during the 4th quarter worth $84,000. Jain Global LLC bought a new position in Korro Bio during the fourth quarter worth about $85,000. Finally, Deutsche Bank AG grew its position in Korro Bio by 241.9% during the fourth quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock worth $102,000 after buying an additional 9,027 shares in the last quarter. 13.18% of the stock is owned by institutional investors.

Key Headlines Impacting Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target (~74% upside vs. the recent share level), which can attract momentum buyers and institutional interest. Raymond James Upgrade
• Positive Sentiment: Multiple large shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed purchases of ~207,100 shares each at about $11.11 (~$2.3M per filing), increasing their stakes — a strong insider/major‑holder vote of confidence that can support the stock. Insider / Major Holder Buys
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for potential treatment of hyperammonemia, is advancing a GalNAc candidate for alpha‑1 antitrypsin deficiency (on track for a development candidate nomination in Q2 2026), and completed an oversubscribed $85M private placement — management says cash runway now extends into H2 2028, reducing near‑term financing risk. Corporate Update & Cash Raise
• Neutral Sentiment: Revenue modestly beat expectations ($1.29M vs. ~$0.42M est.), showing some commercial or other revenue pickup, but the dollar amounts are small relative to R&D burn — limited immediate impact on profitability. Earnings Press Release
• Negative Sentiment: Large quarterly loss: KRRO reported a Q4 EPS loss of ($5.32) vs. consensus (~($1.93)), driving very negative margins and return‑on‑equity metrics — a reminder of high execution risk and binary clinical development outcomes that can trigger volatility. Q4 Results & EPS Miss

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.